Atezolizumab-MMAE
Based on 1 Customer Validation
Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. Atezolizumab-MMAE is composed of a humanized anti-PD-L1 antibody (Atezolizumab) (HY-P9904), a lysosomally cleavable dipeptide linker (valine-citrulline), a tubulin inhibitor (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Atezolizumab-MMAE has a potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effect. Atezolizumab-MMAE has a significantly anti-tumor activity in MC38 xenograft PD-1-humanized immune system mice model.
For research use only. We do not sell to patients.
- Purity: 98.04%
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Atezolizumab-MMAE (Compound 3) (4 µg/mL, 0.5-24 h) can bind to the PD-L1 antigen on the cells membrane and be internalized and transported to lysosomes within 30 min in MDA-MB-231 cells[1].
Atezolizumab-MMAE (0.725-200000 pmol/L, 3 days) has a potent tumor cell inhibitory activity (EC50 of 10.33, 9.75 and 11.94 nM for PD-L1 + MDA-MB-231, PC 9 and A431 cells, respectively) while a weak effect on PD-L1 - Romas cells (EC50: 129.4 nM)[1].
Atezolizumab-MMAE (0.625-10 μg/mL, 48 h) mediates inhibition of the PD1 and PD-L1 interaction and significantly increases levels of IFN-γ when co-cultures with PBMCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231, PC 9, A431, Romas cells
-
Concentration:0.725-200000 pmol/L
-
Incubation Time:3 days
-
Result:Demonstrated a potent inhibitory activity in the MDA-MB-231, PC 9 and A431 PD-L1 + cell lines with EC50 of 10.33 nM, 9.75 nM, and 11.94 nM, respectively.
Exhibited a weak inhibitory activity against the PD-L1 - cell Romas lines with EC50 of 124.9 nM.
-
Cell Line:MDA-MB-231 cells
-
Concentration:4 µg/mL
-
Incubation Time:0, 0.5, 1, 4, 18, 24 h
-
Result:Could bind to the PD-L1 antigen on the membrane of MDA-MB-231 cells at 4 °C.
Be internalized into lysosomes of MDA-MB-231 cells only 30 min.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C57BL/6J-Pdcd1em1 (hPDCD1)/Smoc mice (6-8 weeks old) were inoculated subcutaneously into the upper groin of the lateral hind limbs with log growth-phase of MC38 cells (1 × 106 cells/mouse)[1].
-
Dosage:3 mg/kg
-
Administration:i.p., 2 times per week for 3 weeks following tumor volume reaching about 50-150 mm3, and then measured tumor volume and body weights twice weekly.
-
Result:Produced significant and sustained antitumor effects with a 68% tumor inhibition rate.
Significantly disappeared tumor with tumor regression of 60%, which higher than Atezolizumab alone (tumor regression: 40%).
Had a safety profile with no significant body weight changes.
Chemical Information
-
Appearance Liquid
-
SMILES
[Atezolizumab-MMAE]
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Atezolizumab-MMAE Related Classifications
HY-171572 Related Classifications
Powered by Bioz